Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer
Keywords: سرطان معده; Anti-EGFR therapy; Colorectal cancer; Gastrointestinal cancer; Panitumumab;